Novel CDK2/4/6 inhibitor culmerciclib (TQB3616) plus fulvestrant in previously treated, HR-positive, HER2-negative advanced breast cancer: a randomized, double-blind, phase 3 trial.
Yongmei Yin, Qingyuan Zhang, Tao Sun, Chunfang Hao, Zhihong Wang, Jin Yang, Yongsheng Wang, Yanxia Shi, Jing Sun, Quchang Ouyang, Haichuan Su, Jinsheng Wu, Lu Gan, Meng Han, Liming Gao, Xiaojia Wang, Bing Zhao, Hui Li, Jiuda Zhao, Hongwei Yang, Fangling Ning, Fuguo Tian, Juliang Zhang, Hongmei Sun, Zhaofeng Niu, Hong Zong, Aimin Zang, Xinshuai Wang, Xinyu Qian, Shikai Wu, Jianyun Nie, Lijia He, Ying Cheng, Yanrong Hao, Yi Zhai, Huiping Li, Jingfen Wang, Shihong Wei, Man Li, Yunjiang Liu, Hongqiang Guo, Qun Hu, Lina Liu, Xinghua Han, Ruizhen Luo, Mingli Ni, Xianjun Tang, Zhenhua Zhai, Meiqian Ding, Haibo Wang, Peng Shen, Xian Wang, Lian Liu, Wenyan Chen, Gang Liu, Zhengwen Cai, Zefei Jiang
Signal Transduct Target Ther 10(1) 414
摘要
摘要
CDK2 is a principal mediator of CDK4/6 resistance. Concurrent CDK2/4/6 blockade may be effective in treating HR-positive, HER2-negative advanced breast cancer (ABC). This randomized, double-blind, parallel-controlled, phase 3 trial (ClinicalTrials.gov, NCT05375461) assessed the efficacy of culmerciclib, a CDK2/4/6 inhibitor, plus fulvestrant in ABC. Patients with HR-positive, HER2-negative, locally recurrent or metastatic breast cancer were randomized (2:1) to receive culmerciclib plus fulvestrant or matching placebo plus fulvestrant. Between March 18, 2022 and March 3, 2023, 293 pretreated patients (median age 53.0 years; pre- or perimenopausal 42.3%; bone metastasis 65.2%) were randomized to assigned treatments. At this prespecified interim analysis, culmerciclib plus fulvestrant extended the median investigator-assessed progression-free survival (PFS) significantly, the primary endpoint, as compared with placebo plus fulvestrant (16.6 months, 95% CI 13.8 to not evaluable versus 7.5 months, 95% CI 5.3 to 11.0; hazard ratio 0.36, 95% CI 0.26-0.51; stratified log rank test P < 0.001). Consistent effects were observed across diverse subgroups of patients. At a median follow-up duration of 13.8 months, overall survival was immature. The investigators-assessed objective response rate was 40.2% (95% CI, 33.3-47.5) for culmerciclib compared to 12.1% (95% CI 6.4-20.2) for placebo (stratified Mantel-Haenszel χ2 test P < 0.001). Diarrhea (87.1%) and neutropenia (80.4%) were the most common toxicities with culmerciclib plus fulvestrant. In conclusion, this randomized clinical trial met its primary outcome. Culmerciclib plus fulvestrant is well tolerated and leads to a significant gain in PFS of pretreated HR-positive HER2-negative ABC patients.
KM 提取结果
0 个 Figure · 0 个 KM 面板
其他 Figure(3,默认折叠)
这些图片未产生 KM 曲线结果,不在主页面重复展示。